匹多莫德辅助孟鲁司特治疗咳嗽变异性哮喘的临床疗效

摘要

目的：探讨匹多莫德辅助孟鲁司特对咳嗽变异性哮喘（CVA）患者血清 TNF-α、CRP 及全血嗜酸性粒细胞计数（EOS）表达水平及肺功能的影响。方法100例 CVA 患者按照随机数字表法分为对照组50例，给予止咳平喘常规治疗，并服用孟鲁司特片；研究组50例，在对照组治疗基础上加服匹多莫德口服液。观察治疗前、8周后两组患者血清 TNF-α、CRP、外周血 EOS 水平及肺功能变化，并观察两组日间、夜间咳嗽症状评分的变化情况。结果治疗前两组患者血清 TNF-α、CRP、外周血 EOS 水平、肺功能、日间及夜间咳嗽症状评分比较，差异均无统计学意义（P >0.05）。治疗8周后，研究组 TNF-α、CRP、EOS 水平明显低于对照组（P<0.05），肺功能显著改善（P <0.05），患者日间、夜间咳嗽症状评分均较对照组患者明显改善（P <0.05）。两组总有效率比较，研究组明显高于对照组（P <0.05）。结论匹多莫德辅助孟鲁司特治疗咳嗽变异型哮喘能明显改善咳嗽症状，疗效显著。%Objective To observe the effect of polimod combined with montelukast on the change of serum TNF-α,CRP and blood eosinophil count in patients with cough variant asthma. Methods 100 children with CVA were randomly divided into the control group(50 cases),which were given the basis of conventional therapy and montelukast,and the study group(50 cases),which were given polimod combined with montelukast on the basis of the control group. Their clinical efficacy,TNF-α,CRP,blood eosinophil,lung function and cough symptom scores at day and night 8 weeks after treatment were observed. Results There was no difference in TNF-α,CRP,EOS, lung function and cough symptom scores at day and night in the two groups before treatment(P > 0. 05). 8 weeks af-ter treatment,the expression of TNF-α,CRP and EOS decreased more significantly(P < 0. 05),and their cough symptom scores at day and night decreased more significantly in the study group than in the control group( P <0. 05). The clinical efficacy in the study group was better than that in the control group(P < 0. 05). Conclusion Polimod combined with montelukast could significantly improve cough symptoms and has good clinical effect in treat-ment of children with cough variant asthma.